NEW YORK (360Dx) – RPRD Diagnostics today announced it and Orient Bio have inked a memorandum of understanding that will expand the availability of RPRD's pharmacogenomic testing services to South Korea.

Additionally, Orient Bio will diversify its business to include new areas, including precision medicine and clinical PGx, said RPRD, which stands for Right Patient Right Drug.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.